Congress of the United States

Washington, DC 20510

March 2, 2022

The Honorable Rosa DeLauro Chairwoman Committee on Appropriations U.S. House of Representatives H-307 The Capitol Washington, DC 20515 The Honorable Kay Granger Ranking Member Committee on Appropriations U.S. House of Representatives 1036 Longworth HOB Washington, DC 20515

The Honorable Tom Cole Ranking Member Subcommittee on Labor, Health and Human Services, and Education Committee on Appropriations 1036 Longworth HOB Washington, DC 20515

Dear Chairwoman DeLauro, Ranking Member Granger, and Ranking Member Cole,

As you complete work on the Fiscal Year 2022 Omnibus Appropriations legislation and consider the Department of Health and Human Services (HHS) emergency supplemental request, we urge you to provide additional funds for the procurement and distribution of new COVID-19 therapies.

The COVID-19 pandemic has claimed the lives of more than 940,000 Americans. Yet over two years after the pandemic began, patients in the United States and around the world still have limited access to effective treatments against COVID-19. Although widespread vaccinations have reduced transmission and saved countless lives, the U.S. is still experiencing more than 120,000 new cases, 8,000 hospitalizations, and 1,800 deaths every single day. This burden has strained our hospitals – and the essential health care workforce staffing our intensive care units – to their breaking point.

While the efforts of the federal government and private sector have yielded thirteen COVID-19 therapies deployed under Emergency Use Authorization (EUA), patients still lack access to reliable and effective treatments that reduce hospitalizations and severity of infections. Unfortunately, several authorized treatments have also proven ineffective against the Omicron strain of COVID-19.

Clearly, HHS and the Assistant Secretary for Preparedness and Response (ASPR) require robust resources to procure and distribute new COVID-19 therapies. Giving the American people access to new treatments is one of the federal government's most critical missions during this phase of the COVID-19 response. HHS and ASPR must be prepared to quickly procure and distribute new treatments as soon as the Food and Drug Administration (FDA) issues an EUA. This is the fastest way to ensure innovative new treatments are available for use by state and local public health partners. We recognize the Committee's proposed increase in funding for the

Biomedical Advanced Research and Development Authority (BARDA) in the pending Fiscal Year 2022 Omnibus Appropriations legislation and urge the Committee to consider increasing that funding level in Conference to ensure that the federal government has sufficient resources to fulfill its procurement needs.

According to the National Institutes of Health (NIH) and BARDA, several new investigational COVID-19 therapies are completing clinical studies and could be authorized by FDA in the coming weeks and months. We cannot risk delays in the manufacturing and distribution of these new drugs at a time when patients and our health care system need them the most.

We urge you to include additional funding in the Fiscal Year 2022 Omnibus Appropriations legislation for procurement and distribution of COVID-19 therapies. Rapid deployment of new, effective treatments will reduce the overwhelming burdens placed on our hospital systems and save American lives. Thank you for your attention to this critical matter.

Sincerely,

Bill Pascrell, Jr.

Member of Congress

Mikie Sherrill

Member of Congress

Chrissy Houlahan

Member of Congress

Mussy Houleson

Dwight Evans

Member of Congress

K. Butterfield

Member of Congress

Albio Sires

Member of Congress

Kim Schrier, M.D. Member of Congress Ann McLane Kuster Member of Congress

Daniel T. Kildee Member of Congress

Daniel T. Kiedez

John B. Larson Member of Congress

Donald M. Payne, Jr. Member of Congress Bradley Scott Schneider Member of Congress

Doris Matsui Member of Congress

Don's Matsui

Josh Gottheimer Member of Congress

Donald Norcross Member of Congress

Earl Blumenauer Member of Congress Terri A. Sewell Member of Congress

Jeni Sewell

Linda T. Sánchez Member of Congress

Winds J. Jain

Ron Kind

Member of Congress

Darren Soto

Member of Congress

Jimmy Panetta

Member of Congress

Marc A. Veasey

Member of Congress

Suzan DelBene

Member of Congress